Yatharth Hospital & Trauma Care Services

    YATHARTH
    Pharma
    ₹1,091.10
    Price as of 18 Nov 2026, 9:58 pm IST

    Market cap ₹10,513 Cr

    P/E
    55.19
    Day range
    ₹1,079.70 – ₹1,129.55
    52-week range
    ₹538.25 – ₹1,184.00
    Volume
    2.62 L
    Open
    ₹1,110.95
    Prev close
    ₹1,109.55

    Latest results · Q2 FY27(consolidated)Revenue ₹431 Cr+54.4%Profit ₹48 Cr+17.5%Margin 11.2%YoY vs the same quarter last year

    1 red flag to read up on

    • medium

      Promoter holding falling

      55.80%, down 5.84 pts since 2025-09-30 · 30 Sept 2026

    From NSE and BSE filings. A flag is a reason to read the filing, not a rating.

    Research profile

    Composite 53 / 100

    Factor percentiles

    Value28
    Quality42
    Momentum89
    Low volatility53

    Derived metrics

    Earn. yield
    1.8%
    Graham no.
    ₹292.12
    vs Graham
    -73.2%
    ROE ÷ P/B
    1.8%
    12-1 mom.
    +26.5%
    Return / vol
    1.07
    Magic Formula
    #509
    Piotroski
    2/6
    FCF yield
    -1.0%
    PEG
    3.21

    Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.

    Peer comparison

    All 68 in Pharma
    Largest Pharma companies tracked, with sector medians
    CompanyM-capP/EP/BROEROCEOPMD/ESales YoY
    Sun PharmaSUNPHARMA₹4.49 L Cr40.955.0314.8%21.0%29.0%0.04+11.9%
    Divi's LaboratoriesDIVISLAB₹2.93 L Cr87.1916.8816.2%22.0%43.0%0.00+35.4%
    Torrent PharmaTORNTPHARM₹1.75 L Cr77.889.6726.8%15.0%33.0%0.77+50.8%
    Apollo HospitalsAPOLLOHOSP₹1.27 L Cr56.4011.5522.6%17.0%16.0%0.77+23.0%
    Laurus LabsLAURUSLABS₹1.25 L Cr93.7219.8218.2%18.0%34.0%0.43+33.5%
    Zydus LifesciencesZYDUSLIFE₹1.20 L Cr28.724.3220.1%21.0%24.0%0.50+29.2%
    Dr. Reddy's LabsDRREDDY₹1.17 L Cr41.632.9711.6%13.0%20.0%0.19-1.5%
    Yatharth Hospital & Trauma Care ServicesYATHARTH₹10,513 Cr55.195.6910.0%13.0%24.0%0.25+54.5%
    Sector median₹24,603 Cr43.685.4615.1%17.0%24.0%0.17+22.7%

    Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.

    Latest news

    Updated 8h ago

    Headlines about Yatharth Hospital & Trauma Care Services from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.

    Key metrics

    P/E (TTM)
    56.1
    Price / Book
    5.60
    ROE (FY26)
    10.0%
    ROCE (latest year)
    13%
    Dividend yield
    0.05%

    Moving averages (NSE)

    20-day
    ₹991.1
    Price above
    50-day
    ₹1,017.98
    Price above
    200-day
    ₹837.91
    Price above

    Charts & trends

    From company filings. Amounts in ₹ crore.

    Revenue 3Y CAGR
    +36.2%
    Profit 3Y CAGR
    +37.1%
    Revenue YoY (Sep 2026)
    +54.5%
    Profit YoY (Sep 2026)
    +17.1%
    Operating margin
    24.0%
    Net margin
    11.1%

    Revenue, profit & margin - quarterly

    ₹ crore; a loss shows red. Operating margin below, same periods.

    0 Cr200 Cr400 Cr600 Cr
    • Revenue
    • Net profit

    Operating margin

    Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Sep 20260%15%30%

    Who owns the company

    % of equity by quarter, latest Sept 2026

    Dec '24Mar '25Jun '25Sept '25Dec '25Mar '26Jun '26Sept '260%25%50%75%100%
    • Promoter
    • Public
    • DII
    • FII

    Cash flows

    Where cash came from and went, by fiscal year (₹ crore)

    Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026-1K Cr-500 Cr0 Cr500 Cr1K Cr
    • Operating
    • Investing
    • Financing
    • Free cash flow

    Return on equity

    Net profit over shareholders' equity, by fiscal year

    FY18FY19FY20FY21FY22FY23FY24FY25FY26-20%0%20%40%60%15% screen

    Equity vs debt

    Shareholders' equity against borrowings (₹ crore); the ratio below, same years.

    0 Cr500 Cr1K Cr1.5K Cr2K Cr
    • Equity
    • Debt

    Debt to equity

    Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 20260x2x4x

    Financial statements

    ₹ Crore
    Quarterly results, oldest period first, figures in rupees crore
    Line itemDec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
    Sales167178212218219232258279320342393431
    Expenses120131158163164175193215246262301329
    Operating Profit4647545555576465748092102
    OPM %28%26%25%25%25%25%25%23%23%23%23%24%
    Other Income564345998745
    Interest003221001578
    Depreciation8811161713151924302833
    Profit before tax444443404049595557526166
    Tax %33%13%29%23%24%20%28%25%25%14%26%26%
    Net Profit293830313039424143454548
    EPS in Rs₹3.44₹4.47₹3.54₹3.61₹3.16₹4.02₹4.36₹4.28₹4.71₹4.93₹4.88₹5.25

    From company filings, updated 18 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.

    Working-capital cycle

    Debtor Days113

    +51 days since Mar 2021

    Inventory Days32

    -11 days since Mar 2025

    Days Payable171

    +111 days since Mar 2025

    Cash Conversion Cycle-26

    -88 days since Mar 2021

    Working Capital Days80

    +98 days since Mar 2021

    Strengths, risks & growth

    Incorporated in 2008, Yatharth Hospital and Trauma Care Services Limited is a multi-care hospitals at Noida, Greater Noida, and Noida Extension, Uttar Pradesh. [1]

    Strengths

    • Company is expected to give good quarter
    • Company has delivered good profit growth of 57.1% CAGR over last 5 years
    • Company's working capital requirements have reduced from 101 days to 80.1 days

    Risks

    • Company has a low return on equity of 12.1% over last 3 years.
    • Promoter holding has decreased over last 3 years: -10.5%

    Compounded Sales Growth

    10 Years
    —
    5 Years
    +41%
    3 Years
    +36%
    TTM
    +50%

    Compounded Profit Growth

    10 Years
    —
    5 Years
    +57%
    3 Years
    +38%
    TTM
    +25%

    Stock Price CAGR

    10 Years
    —
    5 Years
    —
    3 Years
    +42%
    1 Year
    +40%

    Return on Equity

    10 Years
    +14%
    5 Years
    +14%
    3 Years
    +12%
    Last Year
    +10%

    Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.

    Shareholding pattern

    Percentage of shares held by each category at each quarter end
    HolderDec 2025Mar 2026Jun 2026Sept 2026Change
    Promoter55.80%55.80%55.80%55.80%0.00 pp
    FII6.18%5.25%5.62%7.05%+1.43 pp
    DII11.02%12.00%10.84%10.94%+0.10 pp
    Public27.01%26.94%27.74%26.21%-1.53 pp

    Filed with NSE for Sept 2026: promoters 55.80%, public 44.20%

    Analysts & fund holdings

    100%
    100% recommend buy
    4 analysts cover the stock
    Valuation vs Health Care Providers & Services
    P/E55.2 vs 45.1
    Sector P/B6.03

    Who holds the shares, quarter by quarter

    Mutual funds 9.56% (-0.18 pp)
    Jun 25
    Sept 25
    Dec 25
    Mar 26
    Jun 26
    Sept 26
    • Promoters55.8%
    • Foreign institutions7.0%
    • Mutual funds9.6%
    • Insurance0.2%
    • Other domestic institutions1.2%
    • Retail14.0%
    • Others12.2%
    Mutual funds holding the most
    Fund% of company% of fund3-month change
    Bandhan Small Cap Fund3.43%1.04%-0.03 pp
    Kotak Multi Cap Fund2.73%0.98%+0.10 pp
    Kotak Balanced Advantage Fund0.96%0.62%+0.10 pp
    Kotak Special Opportunities Fund0.27%1.59%-0.12 pp
    Groww Multicap Fund0.22%1.23%-0.59 pp

    Scorecard

    Performance
    Low
    Valuation
    High
    Growth
    Avg
    Profitability
    High
    Entry point
    Good
    Red flags
    Low

    Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.

    Risk & trend

    From 291 daily sessions to 17 Nov 2026.

    Computed

    Risk

    Volatility (1Y)
    38.7%
    Downside volatility
    34.8%
    Worst 5% of days
    3.6%
    Average of that tail
    4.8%
    Max drawdown (1Y)
    33.8%
    Below its peak
    4.5%

    Against the market

    Beta vs Nifty 50
    0.83
    Correlation
    0.29
    Relative strength (3M)
    +27.2%
    ATR (14)
    3.6%

    Return

    Return 1M
    +11.9%
    Return 3M
    +31.4%
    Return 6M
    +36.0%
    Return 1Y
    +41.6%
    vs 200-day average
    +32.4%

    Momentum

    RSI (14)
    70.0
    MACD histogram
    14.89
    Stochastic %K
    93.7
    ADX (14)
    25.1
    +DI / −DI
    32.0 / 12.7
    Money flow index
    82.2

    Participation

    Delivery (20d avg)
    39.0%
    vs its 60-day baseline
    -0.7 pts
    Volume vs 20-day
    +0.5σ
    Close vs day's VWAP
    +0.1%
    52-week position
    91 / 100

    These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.

    Financial quality

    From consolidated statements to 30 Sept 2026.

    Computed

    Piotroski F-Score

    2 of 6 tested

    • Return on assets positive — passed
    • Operating cash flow positive — not testableno cash flow statement for this period
    • Return on assets improving — failed
    • Cash flow exceeds profit — not testableneeds cash flow and profit against assets
    • Debt to assets falling — failed
    • Current ratio improving — failed
    • No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
    • Operating margin improving — failed
    • Asset turnover improving — passed
    Free cash flow
    -₹112 Cr
    FCF yield
    -1.0%
    Cash conversion
    1.20
    Accruals ratio
    -0.015
    Net debt
    ₹193 Cr
    Net debt / equity
    0.10
    EV / sales
    7.32
    PEG
    3.21
    Capex intensity
    26.4%
    Revenue CAGR
    51.3%
    Profit CAGR
    16.1%

    Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.

    Corporate actions

    • dividend
      Not available — not reported in this filing

      Interim Dividend - Re 0.50 Per Share

      14 Aug 2026
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      21 Sept 2023
      ex-date

    Company announcements

    Company Update
    Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    We hereby submit Certificate under Reg. 74(5) of SEBI (DP) Regulations, 2018 for Q2FY27.

    Company Update
    Announcement under Regulation 30 (LODR)-Newspaper Publication

    We hereby submit Newspaper Publication for the Corrigendum to the Notice of the 1st/2026-27 Extra-Ordinary General Meeting of the Company.

    AGM/EGMPrice-sensitive
    Corrigendum To The Notice Of The 1St/2026-27 Extra-Ordinary General Meeting (EGM) To Be Held On October 15, 2026

    We hereby submit Corrigendum to the Notice of the 1st/2026-27 Extra-Ordinary General Meeting to be held on October 15, 2026.

    Insider Trading / SAST
    Closure of Trading Window

    We hereby submit intimation regarding the Closure of Trading Window for Q2FY27.

    AGM/EGMPrice-sensitive
    Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    We hereby submit the Scrutinizer's Report of 19th Annual General Meeting of the Company held on September 25, 2026.

    AGM/EGMPrice-sensitive
    Voting Results Of The 19Th Annual General Meeting.

    We hereby submit the Voting Results of the 19th Annual General Meeting of the Company held on September 25, 2026.

    AGM/EGMPrice-sensitive
    Shareholder Meeting / Postal Ballot-Outcome of AGM

    We hereby submit the summary of the Proceedings of 19th Annual General Meeting of the Company held today i.e. September 25, 2026.

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    We hereby submit intimation regarding Schedule of Analyst/Investor Meet.

    Company Update
    Announcement under Regulation 30 (LODR)-Newspaper Publication

    We hereby submit the Newspaper Publication of the Notice for the 1st/2026-27 Extra-Ordinary General Meeting of the Company along with the e-voting information.

    AGM/EGMPrice-sensitive
    Shareholder Meeting - EGM On October 15, 2026

    We hereby submit Notice of 1st/2026-27 Extra-Ordinary General Meeting of the Company.

    Company Update
    Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association

    We hereby submit intimation regarding amendments to Memorandum and Articles of Association.

    Company Update
    Announcement under Regulation 30 (LODR)-Issue of Securities

    We hereby submit Issuance and allotment of equity shares and warrants of the Company by way of preferential issue on a private placement basis.

    Company Update
    Announcement under Regulation 30 (LODR)-Press Release / Media Release

    We hereby submit Press Release

    Board Meeting
    Board Meeting Outcome for Outcome Of The Board Meeting

    We hereby submit Outcome of Board Meeting held on September 17, 2026.

    Board MeetingPrice-sensitive
    Board Meeting Intimation for Issuance Of Equity Shares Or Other Securities.

    Yatharth Hospital & Trauma Care Services Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 17/09/2026 ,inter alia, to consider and approve Fund ....

    Filed with BSE (scrip 543950); the last 45 days. Documents open at bseindia.com.

    Documents

    Credit ratings

    Documents open at BSE or the rating agency that issued them.

    Sourced from the company's NSE XBRL filing dated 3 Nov 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.

    FAQ

    Yatharth Hospital & Trauma Care Services: common questions

    Answered from the figures on this page.

    Yatharth Hospital & Trauma Care Services last traded at ₹1,091.10 (NSE, as of 18 Nov 2026). The last session moved it down 1.66%.

    Yatharth Hospital & Trauma Care Services is valued at about ₹10,513 crore (NSE, as of 18 Nov 2026).

    Yatharth Hospital & Trauma Care Services trades at a price-to-earnings ratio of 55.19 (NSE, as of 18 Nov 2026). The P/E compares the share price with earnings per share, so it is only comparable between companies in the same industry.

    Yatharth Hospital & Trauma Care Services has traded between ₹538.25 and ₹1,184.00 over the past 52 weeks, to 18 Nov 2026. It is currently 86% of the way up that range.

    Yatharth Hospital & Trauma Care Services (YATHARTH) is classified under Pharma on this site's screener.